74%
de las cuentas minoristas pierden dinero al operar CFDs con este proveedor.
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierden dinero cuando operan con CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs, y si puedes permitirte asumir el alto riesgo de perder tu dinero.
74%
de las cuentas minoristas pierden dinero al operar CFDs con este proveedor.
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierden dinero cuando operan con CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs, y si puedes permitirte asumir el alto riesgo de perder tu dinero.
Español (Latinoamérica)
Supernus Pharmaceuticals Inc
Abierto
SectorSalud
31.68 1.96
Resumen
Variación precio
24h
Mínimo
30.81
Máximo
32.27
Ingresos | -23M 15M |
|---|---|
Ventas | -1.5M 174M |
P/B Media del Sector | 22.947 57.333 |
BPA | 0.548 |
Margen de beneficio | 8.801 |
Empleados | 674 |
EBITDA | -20M 45M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +23.76% upside |
Próximas Ganancias | 6 may 2025 |
|---|
Capitalización de Mercado | -410M 1.7B |
|---|---|
Apertura anterior | 29.72 |
Cierre anterior | 31.68 |
Puntuación técnica
By Trading Central
Confianza
Very Strong Bullish Evidence
Supernus Pharmaceuticals Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Supernus Pharmaceuticals Inc Esperado
Precio Objetivo
By TipRanks
23.76% repunte
Estimación a 12 meses
Media 38.8 USD 23.76%
Máximo 44 USD
Mínimo 36 USD
De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Supernus Pharmaceuticals Inc Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
